Share Email Print
cover

Proceedings Paper

The potential role of functional inhibition of T regulatory cells by anti-TGF-beta antibody in photodynamic therapy of renal cancer
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy (PDT) has been shown to be an effective locally ablative anti-cancer treatment that has the additional advantage of inducing tumor-directed immune response. We hypothesized that PDT could be combined with anti-transforming growth factor (TGF) beta antibody that does not significantly affect the population of cytotoxic T lymphocytes (CTL) but at the same time, has the potential to decrease the immunosuppressive effects of regulatory T-cells (Treg) mediated by TGF beta. This hypothesis was tested with aTGF-beta antibody combined with BPD-mediated PDT in a BALB/c renal cell carcinoma model. Evidence of positive benefits of the combination therapy over individual treatments alone was obtained.

Paper Details

Date Published: 8 February 2011
PDF: 10 pages
Proc. SPIE 7900, Biophotonics and Immune Responses VI, 790003 (8 February 2011); doi: 10.1117/12.876523
Show Author Affiliations
Pawel Mroz, Wellman Ctr. for Photomedicine, Massachusetts General Hospital (United States)
Harvard Medical School (United States)
Michael R. Hamblin, Wellman Ctr. for Photomedicine, Massachusetts General Hospital (United States)
Harvard Medical School (United States)
Harvard-MIT Division of Health Sciences and Technology (United States)


Published in SPIE Proceedings Vol. 7900:
Biophotonics and Immune Responses VI
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top